Articles tagged with Tumor Cells
Researchers at Karolinska Institutet have identified a specific connection between a protein and an lncRNA molecule that can help decrease fat depots in tumor cells, leading to cell division cessation and cancer cell death. The study contributes to increased knowledge of liver cancer diagnosis and future treatments.
Researchers at Moffitt Cancer Center have identified the molecular and cellular mechanisms that control the formation of tertiary lymphoid structures within tumors. These structures contain immune cells and can promote anti-tumor activity when Tfh cells are introduced, leading to improved outcomes in patients with certain types of cancer.
A study reveals how CSDE1 coordinates skin cell senescence, slowing down cellular function without causing death. This leads to the formation of a firewall against cancer, suppressing tumor growth.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers have revealed mechanisms by which polyps develop into colorectal cancer, setting the stage for improved surveillance utilizing precision medicine. The study found that serrated polyps derive from metaplasia, an abnormal change of cells into non-native tissue.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers have discovered a nanoparticle therapeutic that enhances cancer immunotherapy and treats malignant pleural effusion. The treatment targets the immune system to recognize and eliminate cancer cells, improving survival rates and quality of life for patients.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Researchers analyzed 140 neuroblastoma samples to understand the genetic changes associated with the disease. They found that mutations can disappear and reappear, occurring in distinct sections or individual cells, making targeted therapy less effective.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
Alphataxin, a small-molecule drug, has been shown to significantly suppress tumor growth in mouse models of kidney cancer, including those with lung metastasis. The treatment also increased the formation of CD4+ T cells, which is essential for the immune system's ability to kill tumor cells.
Researchers used imaging mass cytometry to analyze protein expression and cell location in tumor samples. High density of antigen-presenting cells with high PD-L1 and IDO expression was associated with higher pathological complete response rate in patients treated with atezolizumab plus chemotherapy.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
Researchers have developed new preclinical models to understand gastric cancer development and spread. Using these models, they identified Lgr5-expressing tumour cells as responsible for driving gastric cancer growth and spread, establishing them as a potential therapeutic target.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
Researchers at Massachusetts General Hospital have developed a method to detect early signs of tumor cell death using MRI and AI, allowing for non-invasive monitoring of cancer treatment. This approach has shown promise in detecting treatment-responsive regions in mouse brain tumors and healthy human brains.
Scientists have identified a cascade of four proteins that activate the cancer-causing protein ∆Np63α. By inhibiting these proteins, cancer stem cells can be controlled, and tumor growth slowed. This breakthrough offers new therapeutic options for squamous cell carcinoma.
A study found that the MYCN protein creates conflicts between DNA replication and transcription in cancer cells, leading to increased division rates and potential damage. The researchers hope to develop therapies by disrupting the cooperation between MYCN and a molecule called BRCA1.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Researchers at Saarland University have discovered that the lipid and cholesterol metabolism of immune cells collaborating with tumour cells is severely compromised compared to tumour tissue. This finding suggests a possible explanation for why cholesterol-lowering drugs are ineffective against non-small-cell lung carcinoma.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
Researchers identified a subset of dendritic cells that can cloak themselves in tumor proteins and trigger a strong T cell response. Stimulating these dendritic cells may enhance the effectiveness of cancer immunotherapy by slowing the growth of melanoma and colon tumors.
Researchers at UVA Cancer Center discovered how a common gene mutation disrupts cells' ability to suppress tumors. The mutation in the UTX gene forms tiny droplets that help prevent tumor formation.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
Researchers from MUSC Hollings Cancer Center, UCLA Jonsson Comprehensive Cancer Center, and Winship Cancer Institute discovered that pre-surgical anti-PD-1 immunotherapy is safe and effective for OCSCC patients. The studies identified potential molecular biomarkers in blood and tumors to predict treatment response.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers from Kazan Federal University have developed a gene-cell preparation that uses membrane vesicles to target and kill cancer cells. The technology has shown promise in treating various types of cancer, including breast, lung, and colon cancer.
Researchers describe how cancer cells exploit genetic and cellular processes to promote tumor survival and growth. The study found that aneuploidy, a condition of abnormal chromosome number, intersects with the stress response mechanism in cancer cells, leading to immune cell dysregulation.
Researchers at MIT develop a method to decode images of cells in a tissue to determine its phase, which can indicate its developmental stage or cancer progression. The technique uses triangular order parameters to characterize tissue states, allowing for quicker and less invasive diagnoses.
A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
A new study from MIT reveals that calorie-restricted diets slow tumor growth in mice by reducing fatty acid availability, while ketogenic diets have limited effect. The findings offer insight into how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.
Researchers at MIT have developed a new approach to treat cancer by combining chemotherapy, tumor injury, and immunotherapy. In mouse studies, the treatment eliminated tumors completely in nearly half of the mice and showed promise against various types of cancer.
Researchers from UPV/EHU and Biocruces pathologists use game theory to study tumor cell interactions, finding that higher cell diversity may be beneficial for patients. This approach reveals the importance of collective stability in tumor cells' pursuit of better environments.
Scientists developed a fluorescent spray that specifically targets and illuminates cancerous tissue, enabling precise tumor detection and removal during surgery. The innovative approach offers a solution to the challenge of distinguishing between healthy tissue and cancerous cells.
A novel therapy concept allows tumor cells to produce a protein that blocks CD47 and activates immune cells. This approach eradicates tumors by macrophage and NK cell activation in a highly malignant human breast cancer model.
Researchers created polymersomes that target highly invasive cancer cells, delivering anticancer drugs and preventing metastasis. The nanomachines showed strong antitumor effects in breast cancer models, inhibiting lung metastasis and prolonging survival.
Researchers have discovered a way to bring cancer-killing T cells to bear against a specific type of colorectal cancer, showing promising results. The findings may represent a therapeutic strategy to target other types of cancers, and the next step is to further explore how T cells become activated in the tumor environment.
A multicenter study found cardiovascular magnetic resonance imaging to be highly accurate in diagnosing and excluding cardiac tumors. The results show that CMR provides prognostic value beyond clinical factors.
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.
A high-fat diet increases the incidence of colorectal cancer by suppressing MHC-II levels in intestinal cells. This disruption allows cancer cells to grow unchecked. Researchers hope that reconfiguring the gut microbiome and boosting immune recognition molecules can help combat cancer.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
A new imaging technique using PET/MR and a PET tracer directed against CXCR4 shows high accuracy in detecting MALT lymphomas of the stomach, potentially reducing the need for repeated gastroscopies. The study found that [68Ga]Pentixafor PET/MR achieved 97% accuracy in detecting tumours compared to gastroscopy.
Research at CNRS reveals that compressed cell nuclei can lead to DNA damage and accelerated aging in healthy cells. In breast tumors, this damage enables tumor cells to invade neighboring tissues with increased risk of metastasis.
Researchers at Uppsala University developed a new method to track individual cancer cells and their offspring over time. The study found that brain tumour cells are hierarchically organised, but with some degree of flexibility, and that drug treatment influences cell organisation. This breakthrough may lead to the development of target...
Researchers at Weill Cornell Medicine identified club cell factors that inhibit immunosuppressive cells in tumors, leading to increased antitumor T cells and improved effectiveness of PD1 immunotherapy. A
Researchers discover that tumor suppressor genes can prevent the immune system from spotting and destroying malignant cells in mice. The study reveals a surprising new action for many of these defective genes, which trigger mechanisms that prevent the immune system's T-cells from targeting tumors.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
A new study suggests that T cell therapy alone or combined with cancer drug nivolumab is safe and persistent in attacking Hodgkin's lymphoma cells. The treatment showed promising results in patients with relapsed or refractory HL, offering a potential option for those who do not respond to checkpoint inhibitors.
A new study published in Nature Communications reveals that low-risk and high-risk neuroblastoma have distinct cell identities, which can affect survival rates. The researchers identified a progenitor cell type found in fetal adrenal tissue, which may contribute to the development of aggressive neuroblastoma in older children.
Researchers identified a minimal set of defined factors that can convert normal human fibroblast cells to liver cancer cells, providing a mechanistic proof-of-principle for understanding why certain mutations cause cancer in particular tissues.
MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients. The study found that APC mutations lead to increased levels of PD-L1, which allows tumors to evade T-cell function and increase immunosuppression.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
PLOS Medicine features five studies outlining novel strategies for detecting cancer and identifying minimal residual disease. Researchers discuss innovative approaches, including plasma cell-free DNA sequencing and urine tumor DNA detection, to distinguish between benign and malignant tumors.